Cerebras Is Down 22% Since Its IPO Popped. Should You Buy It Now?
Cerebras (CBRS) surged 68% on its IPO day but shares have fallen more than 22% since the May 14 close. The company’s wafer-scale AI chips are designed to reduce memory-to-compute bottlenecks, and it says its Kimi K2.6 trillion-parameter model runs 6.7x faster on a ~20-system cluster. OpenAI signed a $20B deal (up to 750 MW through 2028) and Cerebras had $24.6B in remaining performance obligations; it expects ~15% to be recognized in 24 months.
The stock’s post-IPO drawdown is framed against large contracted backlog (OpenAI) and execution/scale risks (production capacity, TSMC prioritization, tranche deadlines).
Cerebras is the subject of the article’s core thesis: its wafer-scale AI chips, OpenAI $20B deal, and AWS inference disaggregation tie-ins drive the risk/reward.
Near-term trading likely remains volatile: upside hinges on execution toward OpenAI/AWS milestones; downside risk persists if scaling/production or tranche delivery slips.
Background
Cerebras uses wafer-scale engine technology (12-inch wafer filled with chips) aimed at reducing memory/compute bottlenecks in AI inference; the article contrasts scaling concerns with demonstrations like Kimi K2.6 on ~20 systems.
Why it matters
The piece ties Cerebras’s contracted backlog and hyperscaler partnerships to potential revenue growth, while stressing execution risks: data-center build/operations, production scaling via TSMC, and customer concentration tied to OpenAI tranche deadlines.
Market relevance
Material for CBRS traders because it combines (1) large, specific contracted backlog and (2) concrete operational bottlenecks that can accelerate or delay revenue recognition.
Market effects
Highlights wafer-scale AI chip differentiation versus GPU-centric approaches, with read-through to AI inference bottlenecks and data-center buildout needs.
Emphasizes Taiwan Semiconductor Manufacturing capacity/priority risk as a constraint for scaling wafer-scale production.
Large hyperscaler commitments (OpenAI/AWS) reinforce continued global capex for AI infrastructure, but execution risk can shift demand timing across suppliers.
Alternative perspectives
The 22% post-IPO decline may reflect the market discounting execution/scale risk more than the article’s backlog optimism; valuation multiples remain extremely high even under a bullish sales ramp.
Tranche delivery and yield/capacity constraints at TSMC could delay revenue recognition beyond the article’s implied timeline; competitive performance on larger models may not translate into sustained pricing power.
Key entities
- companyCerebras Systems
Wafer-scale AI chipmaker; subject of the article’s buy/don’t-buy debate after a post-IPO selloff.
- customerOpenAI
Signed a $20B deal for up to 750MW of capacity delivered through 2028; most backlog is tied to this agreement.
- customerAmazon Web Services
Pairs Cerebras chips with AWS Trainium via inference disaggregation for different inference workload stages.
- supplierTaiwan Semiconductor Manufacturing
Contract manufacturer for Cerebras wafer-scale chips; capacity prioritization and yield risks are cited as scaling constraints.
